Sandostatin LAR Depot Approved for Carcinoid Syndrome

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

EAST HANOVER, NJ-Novartis Pharmaceuticals has received FDA approval to market Sandostatin LAR Depot (octreotide acetate for injectable suspension) for the treatment of acromegaly and to control the symptoms of metastatic carcinoid tumors and the profuse watery diarrhea associated with vasoactive intestinal peptide secreting tumors (VIPomas).

EAST HANOVER, NJ—Novartis Pharmaceuticals has received FDA approval to market Sandostatin LAR Depot (octreotide acetate for injectable suspension) for the treatment of acromegaly and to control the symptoms of metastatic carcinoid tumors and the profuse watery diarrhea associated with vasoactive intestinal peptide secreting tumors (VIPomas).

In all indications, it is recommended that patients respond to and tolerate initial treatment with subcutaneous Sandostatin (octreotide acetate injection).

Sandostatin imitates the action of somatostatin, an inhibitor of growth hormone and other substances, including insulin growth factor (IGF-1). The depot agent uses a microsphere delivery system to provide slow release of the drug.

Carcinoid syndrome occurs when a carcinoid tumor produces excess hormones, leading to symptoms such as severe diarrhea, wheezing attacks, and flushing of the face. VIPomas, neuroendocrine tumors usually found in the pancreas, secrete VIP, a peptide that modulates intestinal water and electrolyte flow.

The indication for carcinoid syndrome was based on one 6-month trial comparing intragluteal injections of the depot agent (10, 20, or 30 mg every 28 days) with SC injections of Sandostatin three times daily. The results showed that the long-acting agent effectively controlled diarrhea and flushing in most patients.

Recent Videos
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.